Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.14 -0.47%
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $33 million versus the consensus estimate of $29.98 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
